Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia is a research paper published in Cancer (2020). On theSindex it has a DataRank of 0.464. It has been cited 21 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.464
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →University of Texas MD Anderson Cancer Center
Grant: CA016672
National Cancer Institute
Grant: P01 CA049639
NCI NIH HHS
Grant: P30 CA016672
NCI NIH HHS
Grant: P50 CA100632
National Institutes of Health
Grant: 3P01CA049639-08S1
THERAPY OF CML
National Institutes of Health
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals